Clinical Trial Update: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. [Phase 2]

View source ↗

Summary

Phase II trial of BEZ235 (dactolisib) in advanced pancreatic neuroendocrine tumors after failure of mTOR inhibitor therapy has completed with results posted. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• BEZ235 (dactolisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Neuroendocrine Tumors (pNET) | Phase 2 | Status: COMPLETED | Results posted: 2016-05-02